|Earnings per share||-2,605.42 KRW|
|Capitalization (mn)||2,403,774 KRW|
|Net income (mn)||-171,958 KRW|
|Samsung Biologics dividend|
|Samsung Biologics Price to book Value|
|Samsung Biologics Price to Cash-Flow|
|Samsung Biologics Return on Equity|
|Samsung Biologics Financial analysis|
Samsung Biologics is a Health Care industry firm, which concentrates their activity in the Pharmaceuticals and Biotechnology sector. Samsung Biologics headquarters are in Korea, where the firm is listed.
At the time of this analysis, Samsung Biologics stocks were trading at a price of 173,000.00 KRW after significantly growing a 5.20% last month.
According to the graph below, where Price to earnings comparison chart is displayed, Samsung Biologics, has a very negative P/E ratio of -66.40, amount in contrast with the average P/E of the market and companies from Korea, Health Care industry, and Pharmaceuticals and Biotechnology sector. This negative P/E of Samsung Biologics means the company is making a huge loss (really negative net profit), so it is a compulsory for the firm to change their decissions in order to solve the problem. More Samsung Biologics financial data can be accessed on the link.
Samsung Card. Korea. Financials.Samsung Electro-Mech. Korea. Industrials.Samsung Electronics. Korea. Consumer Goods.Samsung Eng. Korea. Industrials.Samsung F & M Ins. Korea. Financials.Samsung Fine Chem. Korea. Basic Materials.
Samsonite Internatio. Hong-Kong. Consumer Goods.Sampo Oyi. Finland. Financials.Salvatore Ferragamo. Italy. Consumer Goods.Salesforce.com. USA. Technology.Saipem. Italy. Oil and Gas.Sainsbury (J). UK. Consumer Services.
All rights reserved
Part of Enciclopedia Financiera Group
Disclaimer: Information on this site is only for informational purposes. Always consult a professional advisor before investing.